Behavioral Optimization for Overcoming Suboptimal Treatment Retention (BUP-BOOSTeR)

Buprenorphine, a medication for opioid use disorder (MOUD), is associated with decreased opioid overdose and all-cause mortality. Treatment outcomes improve if patients remain on MOUD for at least six months, a period recommended by expert guidelines, although most studies report retention on MOUD of 50-65% at 3-6 months. Psychosocial interventions have the potential to improve MOUD treatment retention particularly when applied in combination in efficient delivery systems. The objective of this study is to develop an effective and efficient multicomponent intervention to increase buprenorphine retention at 6 months through an optimization trial.

NCT Number	NCT07607743
Lead Sponsor	Boston University Collaborators: National Institute on Drug Abuse (NIDA)
Conditions	Opioid Use Disorder
Enrollment	240 participants
Start Date	2026-09
Primary Completion	2029-12 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-28